Clinical trial · Observational
Micro RNA Genetic Signature in NSCLC Egyptian Patients
Micro RNA Genetic Signature in Non-small Cell Lung Cancer Egyptian Patients
NCT02445924CI-TRIAL-00024402completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will be carried out on 40 subjects at Chest department Tanta university hospital The subjects will be classified into three groups: * Group I: will include ten non smoker volunteers (control group I). * GroupII: will include ten smoker volunteers (control groupII). * Group III: will include twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Control group 1
- description
- ten non smoker volunteers
- label
- Control group 2
- description
- ten smoker volunteers
- label
- NSCLC patients
- description
- twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
Primary outcomes (1)
- measure
- Detect micro RNA genetic signature pattern in non-small cell lung cancer Egyptian patients assessed using Microarray
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Inclusion criteria for patients: Non small cell lung cancer patients recently diagnosed who did not receive chemotherapy, surgery or radiation therapy. \- Exclusion Criteria: * Exclusion criteria for patients: * Diagnosis of asthma or COPD. * Broncheiactasis. * upper/lower respiratory tract infection in the preceding 4 weeks. * Active pulmonary tuberculosis. * Associated cancer beside lung cancer. * Patients who received chemotherapy, surgery or radiation therapy previous to the sample collection. Exclusion criteria for control subjects: * Diagnosis of asthma or COPD. * Broncheiactasis. * Upper/lower respiratory tract infection in the preceding 4 weeks. * Active pulmonary tuberculosis * Smoking in group I.
References
Publications (3)
- BACKGROUNDTang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013 Nov;22(6):540-8. doi: 10.1097/CEJ.0b013e32835f3be9. PMID 23462458
- BACKGROUNDKeller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009 Oct 6;9:353. doi: 10.1186/1471-2407-9-353. PMID 19807914
- BACKGROUNDLeidinger P, Keller A, Meese E. MicroRNAs - Important Molecules in Lung Cancer Research. Front Genet. 2012 Jan 23;2:104. doi: 10.3389/fgene.2011.00104. eCollection 2011. PMID 22303398